ClinicalTrials.gg
CompletedNCT04167189Updated Jul 2, 2021Results posted

Observational Study to Assess the Frequency of Lidocaine Ineffectiveness in Hard-to-treat ADHD

An Early Phase 1 interventional study of Lidocaine gel in ADHD, sponsored by PhenoSolve, LLC. Completed at 1 site in United States. Open to participants aged 7 Years to 49 Years. Per ClinicalTrials.gov, last updated 2021-07-02.

Sponsored by PhenoSolve, LLC · Early Phase 1, Interventional, and Health services research

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Jan 2018, registered Nov 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
7 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.

Enrollment
548th of 706
28 · median 70
Started
2018
with 36 others
Phase 1
48 of 807
3 open now
Registered
583rd of 807
by date

Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 548th largest by enrollment of the 706 interventional ones that give a count, is one of 37 that started in 2018, is one of 48 in phase 1, and was the 583rd registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 7 Years to 49 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, or all of them as a file.
02

Study summary

This work will assess the prevalence in hard-to-treat ADHD of the ineffectiveness of the anesthetic Lidocaine.

Read the detailed description

Using a non-invasive, pain-free, taste-based approach to assess lidocaine effectiveness, the study will assess the frequency of ineffectiveness in the target population.

03

Conditions studied

04

Who can participate

Ages eligible
7 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: ADHD

Exclusion Criteria for both arms:

  1. known adverse reactions to lidocaine
  2. epilepsy, IQ \<80, severe head trauma, birth weight \<2270 grams, and severe autism;
  3. treatment currently with potassium or potassium-elevating drugs such as renin-angiotensin-aldosterone blockers;
  4. generalized anxiety disorders (but dental-specific anxiety will not be an exclusion because many of these individuals may be ones with anxiety because of painful dental experiences with lidocaine ineffectiveness);
  5. mouth sores;
  6. Ehlers Danlos syndrome, and
  7. red hair.
05

Study design

Phase
Early Phase 1
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Other
    Observational study of prevalence in hard-to-treat ADHD

    Subjects will be tested with lidocaine gel.

    Drug: Lidocaine gel

Interventions

  • Septodont 5% oral lidocaine gel (NDC 0362-0221-10), 75 mg

    Also known as: Intervention

06

What researchers measure

Primary outcomes

  1. Observational Study: Number of Participants With Lidocaine Ineffectiveness by Taste Test in Hard-to-treat ADHD

    Subjects will be asked to identify each taste and its intensity.

    Time frame: on day of testing, approximately 30 minutes for clinic visit

07

Results

Posted Jul 2, 2021
Limitations and caveats
This was an observational study without controls, as there were no controls available at the site. NeurAbilities is a clinic dedicated to treating patients with neurological diagnoses. To do statistics, the study will need to be repeated at a site that can provide controls.

Participant flow

Participant flow — Overall Study
MilestoneHard-to-treat ADHD
Started28
Completed28
Not completed0

Outcome measures

PrimaryObservational Study: Number of Participants With Lidocaine Ineffectiveness by Taste Test in Hard-to-treat ADHD

Subjects will be asked to identify each taste and its intensity.

Time frame:
on day of testing, approximately 30 minutes for clinic visit
Reported as:
Count of participants · Participants
Observational Study: Number of Participants With Lidocaine Ineffectiveness by Taste Test in Hard-to-treat ADHD
ParticipantsHard-to-treat ADHD
Lidocaine effective (got numb)1
Lidocaine ineffective (did not get numb)27

Adverse events

Collected over on day of testing, approximately 60 minutes for clinic visit. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Hard-to-treat ADHD0/28 (0%)0/28 (0%)0/28 (0%)

Baseline characteristics

Subjects who completed the study

Age, Continuous
Age, Continuous(years)Hard-to-treat ADHD
Mean16 ± 7.0
Sex: Female, Male
Sex: Female, Male(Participants)Hard-to-treat ADHD
Female7
Male21
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Hard-to-treat ADHD
Hispanic or Latino3
Not Hispanic or Latino25
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Hard-to-treat ADHD
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White22
More than one race6
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Hard-to-treat ADHD
United States28
Hard-to-treat ADHD (does not respond to available ADHD drugs)
Hard-to-treat ADHD (does not respond to available ADHD drugs)(Participants)Hard-to-treat ADHD
Count of participants28
08

Study locations

1 site
  • NeurAbilitis
    Voorhees, New Jersey 08043, United States
09

References and documents

Publications

  • Infante MA, Moore EM, Nguyen TT, Fourligas N, Mattson SN, Riley EP. Objective assessment of ADHD core symptoms in children with heavy prenatal alcohol exposure. Physiol Behav. 2015 Sep 1;148:45-50. doi: 10.1016/j.physbeh.2014.10.014. Epub 2014 Oct 23. PubMed 25447751 ↗
  • Levitt JO. Practical aspects in the management of hypokalemic periodic paralysis. J Transl Med. 2008 Apr 21;6:18. doi: 10.1186/1479-5876-6-18. Erratum In: J Transl Med. 2014;12:198. Dosage error in article text. PubMed 18426576 ↗
  • Nakai Y, Milgrom P, Mancl L, Coldwell SE, Domoto PK, Ramsay DS. Effectiveness of local anesthesia in pediatric dental practice. J Am Dent Assoc. 2000 Dec;131(12):1699-705. doi: 10.14219/jada.archive.2000.0115. PubMed 11143733 ↗
  • Segal MM. We cannot say whether attention deficit hyperactivity disorder exists, but we can find its molecular mechanisms. Pediatr Neurol. 2014 Jul;51(1):15-6. doi: 10.1016/j.pediatrneurol.2014.04.014. Epub 2014 Apr 18. No abstract available. PubMed 24938135 ↗
  • Segal MM, Rogers GF, Needleman HL, Chapman CA. Hypokalemic sensory overstimulation. J Child Neurol. 2007 Dec;22(12):1408-10. doi: 10.1177/0883073807307095. PubMed 18174562 ↗
  • Segal MM, Douglas AF. Late sodium channel openings underlying epileptiform activity are preferentially diminished by the anticonvulsant phenytoin. J Neurophysiol. 1997 Jun;77(6):3021-34. doi: 10.1152/jn.1997.77.6.3021. PubMed 9212254 ↗
  • Teicher MH, Polcari A, Fourligas N, Vitaliano G, Navalta CP. Hyperactivity persists in male and female adults with ADHD and remains a highly discriminative feature of the disorder: a case-control study. BMC Psychiatry. 2012 Nov 7;12:190. doi: 10.1186/1471-244X-12-190. PubMed 23134619 ↗
  • Mintz M, Badner V, Feldman LK, Mintz P, Saraghi M, Diaz J, Mezhebovsky I, Axelrod I, Gleeson J, Liu C, Smith C, Chow H, Zurakowski D, Segal MM. Lidocaine Ineffectiveness Suggests New Psychopharmacology Drug Target. Psychopharmacol Bull. 2022 Jun 27;52(3):20-30. PubMed 35815177 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The investigators plan to submit for publication descriptions of what was accomplished, and the evaluations as described in the study, including the incidence of lidocaine ineffectiveness in those with ADHD and in the general population.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: 3 months

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Mar 2020, 26 months.

Results were first posted in Jul 2021, 1 year 3 months after primary completion.

Of 21 industry-sponsored phase 1 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 2 months of starting (the median); a quarter within 1 and three quarters within 7. This study's 26 months is above that.

Counting every sponsor, half of 35 studies reached it within 9 months; a quarter within 2 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2019
First posted
Nov 18, 2019
StartActual
Jan 20, 2018
Primary completionActual
Mar 30, 2020
CompletionActual
Mar 30, 2020
Results first posted
Jul 2, 2021
Last update
Jul 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04167189
Lead sponsor
PhenoSolve, LLC
Collaborators
NeurAbilities (formerly CRCNJ)
Responsible party
Sponsor
First posted
Nov 18, 2019
Start date
Jan 20, 2018
Primary completion
Mar 30, 2020
Completion
Mar 30, 2020
Results posted
Jul 2, 2021
Last update
Jul 2, 2021

Study contacts

Michael Segal, MD PhD
principal investigator · PhenoSolve, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion